MorphoSys AG Reports First Nine Months and Third Quarter 202

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results 16.11.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 16, 2022 MorphoSys AG...

Related Keywords

Germany , Louisiana , United States , New Orleans , United Kingdom , Planegg , Bayern , Massachusetts , Boston , Canada , American , Monjuvi Minjuvi , Thomas Biegi , Tim Demuth , Julia Neugebauer , Eamonn Nolan , Jean Paul Kress , Md Tim Demuth , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Xencor Inc , Linkedin , Twitter , Drug Administration , Nasdaq , Distribution Services , Exchange Commission , Morphosys Group Key Figures , Development Rd Expenses , Share Of Loss Associates , Society Of Hematologic Oncology , Interim Statement , First Nine Months , Third Quarter , Chief Executive Officer , Data Highlights , Hematologic Oncology , Molecular Targets , American Society , Hematology Annual Meeting , Chief Research , Development Officer , Malte Peters , Events After , Net Loss , Royalty Pharma , Full Year , Sys Group Key Figures , Impairment Losses , Tax Benefit , Net Profit , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Janssen Biotech , Morphosy Annual Report , Corporate News , Regulatory Announcements ,